M. Jahangir Alam

M. Jahangir Alam

Auto-generated profile, based on publicly available information

M. Jahangir Alam

University of Houston College of Pharmacy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2022 in Data in Brief
Verified
Journal Article
Open access
NMNur Nashyiroh Izayati Mastor
Nur Nashyiroh Izayati Mastor
VSVijay Kumar Subbiah
Vijay Kumar Subbiah
WBWan Nazirah Wan Abu Bakar
Wan Nazirah Wan Abu Bakar
KBKhurshida Begum
Khurshida Begum
MAM. Jahangir Alam
M. Jahangir Alam
MHMohammad Zahirul Hoque
Mohammad Zahirul Hoque
An Enterococcus faecalis strain SHH039 was isolated from a 68 year old man who was hospitalised with cholecystitis. The genomic sequence of this isolate which had a size of 2,990,081 bp and 2,663 proteins with functional assignments is presented here. Analysis of the genome revealed Enterococcus faecalis with multiple antibiotic resistance genes which may be associated with acute cholecystitis. It may be not clear if the infection symptoms are the consequence of enterococci manifestation. However, this opportunistic organism may play a minor role in the disease.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CLChris Lancaster
Chris Lancaster
JMJacob McPherson
Jacob McPherson
MAM Jahangir Alam
M Jahangir Alam
KBKhurshida Begum
Khurshida Begum
EKEkramul Karim
Ekramul Karim
KGKevin W Garey
Kevin W Garey
Ibezapolstat (IBZ) is a non-absorbable antimicrobial currently in phase 2 clinical trials for the treatment of Clostridioides difficile infection (CDI). In vitro and human studies have shown potent activity of IBZ against C. difficile but selective activity against other beneficial Gram-positive gut microbiota shown to reduce the risk of recurrent CDI. As the target DNA Pol IIIC enzyme is present in most Gram-positive species, the reasons for this selectivity are unclear. The purpose of this study was to assess the selectivity of IBZ against Gram-positive gut commensal microbiota. Using stool samples and microbiome data from the phase 2a CDI study, concentration changes in certain Gram-positive commensals were analyzed by qPCR over time in patients with CDI given IBZ. Gram-positive isolates were cultured from stool, speciated, and MIC determined. AlphaFold2-enabled drug docking was used to assess in silico differences in drug-binding residue sites predictive of IBZ binding across a large range of Gram-positive bacteria isolated from the stool. From the phase 2a study, relative abundance of Firmicutes and concentrations of certain species (Clostridium leptum and Clostridium coccoides groups) increased while on IBZ therapy. Thirty-six strains were isolated from Families Clostridiaceae (n=25), Enterococcaceae (n=3), Lachnospiraceae (n=3), and Peptostreptococcaceae (n=5). MIC50/90 values averaged 1.5/3.0 ug/mL (geometric mean) for strains isolated at baseline and early therapy (days 1-3) and 12/126 ug/mL for samples taken later on therapy and three-day follow-up. Two strains isolated at day 30 follow-up were < 2 ug/mL and another was >128 ug/mL. All C. difficile strains were IBZ susceptible (MIC<2 ug/mL). Using a protein sequence alignment from more than 500 Firmicute PolC sequences, potential contact points of interest were identified that helped explain the selectivity of Ibezapolstat. Increased Firmicute abundance and concentration may be explained by selection of non-susceptible Firmicute species during therapy. Distinct IBZ drug-binding residues in the Pol IIIC enzyme may explain this selectivity. Structural biology experiments will confirm these results. Eugenie Basseres, PhD, Accurx: Grant/Research Support Kevin W. Garey, PharmD, MS, Acurx: Grant/Research Support|Ferring: Advisor/Consultant|Paratek: Grant/Research Support

16 October 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
AMAbdulwhab Shremo Msdi
Abdulwhab Shremo Msdi
KBKhurshida Begum
Khurshida Begum
Chenlin HuChenlin Hu
Chenlin Hu
NSNeil Shaw
Neil Shaw
AMAlexander Mai
Alexander Mai
KGKevin W Garey
Kevin W Garey
Antibiotics can negatively affect gut microbiome composition and function. However, preclinical evaluations of antibiotic effects on the microbiome are rarely undertaken. The purpose of this study was to characterize pharmacokinetics and metagenomic profiles of PolC inhibitor compounds compared to linezolid in a neutropenic murine thigh infection model. Neutropenic mice thighs were inoculated with methicillin-resistant Staphylococcus aureus (MRSA) and dosed orally starting 1 h later with ACX-728, ACX-801, ACX-978, or linezolid. Untreated control mice were euthanized at 1 h for baseline data, and a second untreated group were euthanized at 24 h after the start of dosing, when all remaining mice were euthanized. At euthanasia, thigh muscles were excised for MRSA quantification, and fecal pellets, colon tissue, and plasma samples were collected for drug concentration and microbiome analyses. All PolC inhibitors were detectable in plasma and feces at 25 h. Compared with linezolid, PolC inhibitors maintained greater gut microbial richness and diversity in this acute murine infection model. PolC-treated samples preserved overall community structure and Bacteroidota dominance, whereas linezolid induced marked disruption, with secondary expansion of Pseudomonadota , primarily Escherichia coli . Microbial pathway analysis showed preservation of community-level metabolic function for PolC inhibitors but marked disruption by linezolid. Compared to controls, linezolid produced a 4.4 log reduction in MRSA colony-forming unit per gram, while the PolC inhibitors produced a mean log reduction of 0.4–2.5 per group. In these exploratory studies, PolC inhibitor compounds preserved anaerobic community structure and fermentative capacity, whereas linezolid induced depletion of healthy commensals and expansion of aerotolerant taxa. These findings highlight the importance of microbiome-informed antibiotic evaluation in preclinical studies. Larger preclinical and clinical studies are warranted to confirm these findings. IMPORTANCE: This study evaluated the class effect of PolC inhibitors on the microbiome as part of the preclinical development plan for systemic PolC inhibitors. Similar to the non-absorbable antibiotic, ibezapolstat, a narrow effect on the microbiome was observed with these novel compounds.